Edesa Biotech Shares outstanding
What is the Shares outstanding of Edesa Biotech?
The Shares outstanding of Edesa Biotech, Inc. is 18.154M
What is the definition of Shares outstanding?
Shares outstanding are all the shares of a corporation or of a financial asset that have been authorized, issued and purchased by investors and are held by them.
= issued shares - treasury shares
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Shares outstanding of companies in the Health Care sector on NASDAQ compared to Edesa Biotech
What does Edesa Biotech do?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Companies with shares outstanding similar to Edesa Biotech
- Zhongchao has Shares outstanding of 18.103M
- New Destiny Mining has Shares outstanding of 18.106M
- Gulfport has Shares outstanding of 18.107M
- Aptose Biosciences Inc has Shares outstanding of 18.109M
- Vigil Health Solutions has Shares outstanding of 18.128M
- Orca has Shares outstanding of 18.151M
- Edesa Biotech has Shares outstanding of 18.154M
- New Home Inc has Shares outstanding of 18.161M
- Career Point has Shares outstanding of 18.163M
- Phio Pharmaceuticals has Shares outstanding of 18.164M
- Vasta Platform has Shares outstanding of 18.169M
- Cosmo Films has Shares outstanding of 18.173M
- V-Mart Retail has Shares outstanding of 18.174M